|Articles|August 10, 2022
Validation of ICON™ Automated Cell Counting and Viability Assay (August 2022)
Author(s)Advanced Instruments
This benchmarking study compares the Advanced Instruments Solentim ICON™ viability assay to the performance of a commercially available cell counter. The results demonstrate lower variation, increased precision, and time savings.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
